<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769781</url>
  </required_header>
  <id_info>
    <org_study_id>CR013-01</org_study_id>
    <nct_id>NCT01769781</nct_id>
  </id_info>
  <brief_title>Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence</brief_title>
  <official_title>Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Endocrinology and Reproductive Medicine, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Endocrinology and Reproductive Medicine, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will
      be tested for the treatment of women with endometriosis recurrence compared with classical
      GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will
      be the outcomes for establishing which medical treatment is the best in endometriosis
      recurrence treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing
      recurrence after surgery at least in 20-50% after 5 years of follow-up. Aromatase inhibitor
      plus GnRH analog may be more effective than GnRH agonist alone in the treatment of
      endometriosis recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free time</measure>
    <time_frame>24 months</time_frame>
    <description>time without pain symptoms due to the disease recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time of pain disappearance</measure>
    <time_frame>24 months</time_frame>
    <description>time needed during treatment to improve pain symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>reduction of endometriosis lesions</measure>
    <time_frame>24 months</time_frame>
    <description>endometriosis lesions regression during treatment evidenced by MRI scan</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>anastrazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH analog alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrazole</intervention_name>
    <description>combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months</description>
    <arm_group_label>anastrazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH analog alone</intervention_name>
    <description>treatment for three months with GnRH analog (leuprolide acetate) alone</description>
    <arm_group_label>GnRH analog alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women affected by endometriosis showing recurrence of pain symptoms, previous surgery
             for endometriosis

        Exclusion Criteria:

          -  presence of other systemic diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>marco sbracia, md</last_name>
    <role>Study Chair</role>
    <affiliation>CERM-HUNGARIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cerm-Hungaria</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2013</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</investigator_affiliation>
    <investigator_full_name>Fabio Scarpellini</investigator_full_name>
    <investigator_title>PRINCIPAL INVESTIGATOR</investigator_title>
  </responsible_party>
  <keyword>endometriosis recurrence</keyword>
  <keyword>pelvic pain</keyword>
  <keyword>aromatase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

